Tal Zak­s' post-Mod­er­na fu­ture is now in view as he joins biotech VC blue-chip­per Or­biMed

It’s hard to imag­ine what comes next for a physi­cian-sci­en­tist who’s de­vel­oped one of the most lu­cra­tive vac­cines in bio­phar­ma his­to­ry. On Mon­day — a month af­ter leav­ing his post at Mod­er­na — Tal Zaks cleared up some of the mys­tery, an­nounc­ing a new gig at a lead­ing start­up en­gine.

Zaks is join­ing Or­biMed along with Sheila Gu­jrathi, for­mer CEO and co-founder of Gos­samer Bio. They’ll be tak­ing ven­ture part­ner and ven­ture ad­vi­sor roles, re­spec­tive­ly, to help find and fund the next break­throughs in drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER